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Absence of methylation of CpG dinucleotides within the
promoter of the breast cancer susceptibility gene BRCA2
in normal tissues and in breast and ovarian cancers
N Collins, R Wooster* and MR Stratton
Section of Molecular Carcinogenesis, Haddow Laboratories, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
Summary Germline mutations of the BRCA2gene on chromosome 13q12-ql3 predispose to the development of early-onset breast cancer
and ovarian cancer. Loss of heterozygosity detected using chromosome 13q markers in the vicinity of BRCA2 is observed in most cancers
arising in carriers of germline BRCA2 mutations and also in 30-50% of sporadic breast and ovarian cancers. However, somatic mutations of
BRCA2 are extremely rare in sporadic cancers. We have examined the hypothesis that expression of the BRCA2 gene may be suppressed
in sporadic breast cancers by a mechanism that is associated with increased methylation of cytosine residues in the promoter region. Using
a Hpall/Mspl digestion-polymerase chain reaction based assay, the presence of 5-methylcytosine in three CpG dinucleotides within the
BRCA2 promoter was assessed in 18 breast or ovarian cancer cell lines, in an SV40 large T antigen immortalized cell line derived from
normal breast epithelial cells, in 64 primary sporadic breast cancers and peripheral blood leucocytes from these cases and in a number of
other normal human tissues. Methylation was not detected in any of the tissues examined, suggesting that this mechanism of transcriptional
repression is unlikely to explain the absence of somatic mutations in sporadic cancers.
Germline mutations of the BRCA2 gene on chromosome
13ql2-13 predispose to the development of early-onset breast
cancer and ovarian cancer (Wooster et al, 1995). Most germline
mutations in BRCA2 are predicted to result in truncation (Wooster
et al, 1995; Miki et al, 1996; Tavtigian et al, 1996) and hence inac-
tivation of critical functions of the encoded protein. Tumours
arising in carriers of BRCA2 germline mutations usually exhibit
loss of heterozygosity (LOH) of chromosome 13q polymorphic
markers flanking BRCA2. The allele lost is the wild-type allele
inherited from the non-mutation carrying parent (Collins et al,
1995), a pattern that is characteristic of a tumour-suppressor gene
and that is predicted to result in the absence of the functional
protein in the tumour cell.
In addition to germline mutations that confer susceptibility to
neoplasia, many cancer predisposition genes including RB]
(T'Ang et al, 1988), p53 (Nigro et al, 1989), VHL (Shuin et al,
1994), NF-I (Li et al, 1992), NF-2 (Lekanne Deprez et al, 1994),
APC (Powell et al, 1992), MTS] (Caldas et al, 1994) and WTI
(Gessler et al, 1994) are somatically mutated in sporadic cancers.
These somatic mutations are usually associated with a high
frequency of LOH in the vicinity of the susceptibility gene in the
relevant sporadic cancers. Loss of heterozygosity at the BRCA2
locus has been observed in 30-40% of sporadic primary breast
cancers (Devilee et al, 1989; Cleton Jansen et al, 1995;
Kerangueven et al, 1995) and in approximately 50% of sporadic
ovarian cancers (Yang Feng et al, 1993; Takahashi et al, 1996).
However, exhaustive analyses of many sporadic breast, ovarian
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and other cancers have indicated that somatic mutations in BRCA2
are very rare (Foster et al, 1996; Lancaster et al, 1996; Miki et al,
1996; Takahashi et al, 1996; Teng et al, 1996).
For certain tumour-suppressor genes an alternative, epigenetic
mechanism ofinactivation within tumour cells has been proposed.
In some cancers, normally unmethylated cytosine residues within
or near the promoter region of genes such as MTSJ (pl6INK4a)
(Gonzalez Zulueta et al, 1995), RBI (Ohtani Fujita et al, 1993),
E-cadherin (Yoshiura et al, 1995) and VHL (Herman et al, 1994)
become methylated. The altered methylation status is transferred
to daughter cells as a stable epigenetic change. Although the func-
tional consequences of this change in methylation status are not
fully understood, it is believed to be associated with and probably
causally implicated in transcriptional repression of the tumour-
suppressor gene. In such cancers, the requirement for somatic
mutations is thought to be obviated by a substantial reduction
in transcript levels of the tumour-suppressor gene. The rarity of
somatic mutations in BRCA2 has therefore prompted us to
examine the methylation status of a CpG island in the BRCA2
promoter region in normal and neoplastic tissues.
MATERIALS AND METHODS
DNA and RNA were isolated by conventional methods. To evaluate
methylation of the cytosine within the CpG dinucleotide of
HpaIllMspI sites within the BRCA2 promoter, each fragment was
amplifiedfrom 100 ng ofgenomic DNA after (a) digestion ofthe test
DNA with HpaII, (b) digestion ofthe test DNA with MspI or (c) no
restriction enzyme treatment. (All restriction enzyme digestions were
carried out for 16 h according to the manufacturer's recommended
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conditions.) CCGG sequences are digested equally efficiently by
MspI and HpaII. However, CmeCGG sequences are digestedbyMspI
but not HpaIl. Therefore, in the absence of pretreatment with a
restriction enzyme, PCR amplification will proceed over the intact
HpaII/MspI site. At an unmethylated HpaII/MspI site, both enzymes
will digest efficiently, cleave the DNA segment between the PCR
primer sequences and prevent PCR amplification. At a methylated
HpaIYMspI site, MspI will again digest efficiently and inhibit the
subsequent PCR. However, HpaII digestion will be inhibited and
hence amplification ofthe fragment inthe PCR shouldbe successful.
To control for variations in the quality of test DNA and fluctua-
tions in the efficiency of the PCR, an additional pair of primers
that amplify a segment of BRCA2 exon 11 was included in each
PCR. This fragment does not include a HpaIlYMspI restriction site
and therefore should amplify under all conditions.
The sequences ofthe primers used in these analyses were:
site 1- 5'-GAAGCGTGAGGGGACAGATT-3'
5'-GTAAGCTGACAAAAACCGC-3'
site 2 - 5'-GCGGTTTTTGTCAGCTTACT-3'
5'-CACGCTGGACTGGGACTG-3'
site 3 - 5'-TCTTCCGCAGTCCCAGTC-3'
5'-ACCTTTCTCTCAGGCATG-3'
control for site 1- 5'-AGAATTGGAAAAAGAAGAGGAG-3'
5'-GATTGGCAACACGAAAGGTAAA-3'
control for site 2 - 5'-TTCAACAAGACAAACAACAGT-3'
5'-TGTCAGTTCATCATCTTCCATAAA-3'
control for site 3 - as control for site 1.
The PCR conditions for all three sets of primer pairs were as
follows: the first ten cycles constituted a 60°C to 50°C touchdown
PCR (two cycles each at annealing temperatures 60°C, 58°C,
56°C, 54°C and 52°C) and subsequently 18 cycles of 1 min at
94°C (denaturation), 1 min at 50'C (annealing) and 1 min at 72°C
(extension). The products were electrophoresed on 4% (site 1) or
2% (sites 2 and 3) Metaphor agarose gels containing ethidium
bromide and visualized over UV light. In some experiments, the
PCR primers were end labelled with [T32P]ATP using T4 poly-
nucleotide kinase before incorporation into the PCR. The products
of these amplifications were electrophoresed on 6% denaturing
polyacrylamide gels and analysed using a Molecular Dynamics
phosphorimager and Image Quant software.
For the analysis ofBRCA2 expression, 1 ig of RNA from each
of the cell lines was used to generate cDNA by reverse transcrip-
tion (using a commercially available kit). A 1 ,l aliquot of the
resulting cDNA was amplified in a PCR in which two pairs of
primers were present. The sequences ofthe primers used were:
BRCA2 - 5'-TATGTCCAAATTTAATTGATAAT-3'
5'-TTCCTTATTACATTTTGCTTCTTTAT3'
and Actin - 5'-GATGGAGTTGAAGGTAGTTTCGTG-3'
5'-GAGCGGGAAATCGTGCGTGACATT3'.
The products of the RT-PCR were electrophoresed on 2%
agarose gels and then blotted by capillary transfer onto HybondN+
for 16 h in 0.4 M sodium hydroxide. The membranes were
hybridized to two probes, one to detect actin and one to detect
BRCA2. The sequences ofthe probes were:
BRCA2 - 5'-CTGTAGCTlTTGAAGAATGCAG-3'
Actin - 5'-GAGCGGGAAATCGTGCGTGACATT-3'
The results were analysed using the phosphorimager and software
as above.
RESULTS
Identification of a CpG island close to the 5' end of
BRCA2
Genomic DNA sequence at the 5' end of the BRCA2 gene
was identified from approximately one megabase of DNA
sequence flanking and including BRCA2. This sequence is
available at ftp://ftp.sanger.ac.uk/pub/human/sequences/1 3q,
ftp://genome.wustle.edu/pub/gscl/brca2 and Genbank accession
number Z73360. Within a 1.1-kb region extending from -380
to + 700 (with 0 being the transcriptional start site of BRCA2;
Figure 1), the G + C content exceeds 60% and there is an elevated
CpG/GpC ratio (Bird, 1986). The high density of CpG dinucleo-
tides and the location of this region are characteristic of the 'CpG
islands' that are found in the vicinity of the transcriptional start
site of approximately 60% of genes (most known 'housekeeping'
and some tissue-specific genes) (Bird, 1986). This 1.1-kb region
also contains short sequences corresponding to SPI, USF, AP2
and CP2 transcription factor recognition sites, which are often
found within the promoters of genes. However, no TATA or CAAT
box was observed.
Analysis of methylation status in the BRCA2CpG
island
Seven HpaIVMspI restriction endonuclease sites (CCGG) were
identified within the CpG island at the 5' end of BRCA2, and
oligonucleotide PCR primers were designed to amplify each site
independently. However, because of the high G + C content of
the DNA, only three ofthese fragments amplified successfully in
the PCR.
Representative examples ofresults obtained from these studies
are shown in Figure 2. At all three HpaIVMspI sites within the
CpG island, methylation was not detected in peripheral blood
leucocytes from the two sporadic breast cancer cases illustrated.
In the tumours from these two cases the pattern of PCR amplifi-
cation is identical, suggesting that methylation is not present in
neoplastic cells either. Similar studies were performed on 64
primary sporadic breast cancers and matched leucocyte DNAs,
on 18 breast and ovarian cancer cell lines, on one cell line
derived from normal breast epithelial cells that had been immor-
talized with a temperature sensitive SV40 large T antigen and on
samples from normal breast, normal bladder, normal colon and
normal liver. In no sample was the presence of 5-methylcytosine
detected at any of the three sites observed. Haematoxylin and
eosin (H + E)-stained 10-gm sections taken from the fragments
of primary tumour used in these experiments were reviewed and
demonstrated that 49 were composed of at least 50% tumour
cells. This set of breast cancers has been previously studied and
showed allele loss on chromosome 13q in 30% of cases (Cleton-
Jansen et al, 1995).
To evaluate the sensitivity of the assay, the methylation status
of a HpaIVMspI site in exon 23 of BRCA2 was examined.
Predigestion with MspI abolished PCR amplification of the frag-
ment containing this restriction site. However, digestion with
HpaII left the site intact, permitting PCR amplification (Figure 3).
The results indicate that this site within the coding sequence of
BRCA2 is methylated and therefore that the assay is sensitive to
the methylation status.
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Figure 1 The sequence of the 5' CpG island associated with the BRCA2gene. CpG dinucleotides are indicated by an asterisk, putative Spl recognition sites
are underlined and Hpall/Mspl restriction sites are boxed. The high G + C content (62% compared with 30% in total genomic DNA), the increased ratio of
CpG-GpC (1:1 compared with 1:5 in total genomic DNA) and the presence of several transcription factor recognition sites suggest that this region is involved
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Figure 2 Examples of the band patterns seen on agarose gels after Hpall/Mspl digestion and PCR amplification with two pairs of primers (as explained in the
text). The Mspl- or Hpall-digested samples do not amplify across the restriction site, indicating that the site has been cleaved and that the CpG at that position
is unmethylated. This is observed at all three sites tested, in both the blood and the tumour DNA, for all the samples that were examined. In every case, the
control band amplified, indicating that the absence of a PCR product was not due to a failed PCR. In some of the Hpall/Mspl-digested samples, especially at
site 1, a residual band is seen at the same position as that of the undigested DNA sample when amplified across the restriction site. This is probably due to an
incomplete digest of the genomic DNA and is seen as frequently in the blood DNA samples as in the tumour DNA
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Figure 3 (A) Phosphorimager traces of a tumour DNA subjected to the methylation assay at each of the three restriction enzyme sites within the BRCA2
promoter. The PCR is unable to amplify across any of the restriction sites (S) when the DNA has been digested with Mspl or Hpall, indicating that the CpG
dinucleotides in this region are not methylated. The control band (C) is present in each case showing that a negative result is not due to a failed PCR.
(B) Phosphorimager traces of a blood/tumour pair subjected to the methylation assay at a CCGG site in exon 23 of BRCA2. The results indicate that the CpG
dinucleotide in this Hpall/Mspl site is methylated, as the Mspl digestion is able to cleave the site but digestion with Hpall leaves the site intact in both the blood
and the tumour DNA
Expression of BRCA2
We have examined expression ofBRCA2 in the breast and ovarian
cancer cell lines using reverse transcription polymerase chain reac-
tion (RT-PCR) assay for BRCA2 alone and an RT-PCR assay for
BRCA2 in competition with actin (the competition for PCR
reagents between primers forBRCA2 cDNA with primers for actin
cDNA in the RT-PCR is equivalent to normalizing variations in
loading ofRNA between lanes on a Northern blot by hybridization
with an actin probe). The results show that there is variation in the
expression ofBRCA2 (Figure 4). Indeed, in one ovarian cancer cell
line, we were unable to detect BRCA2 expression in BRCA2-actin
competitive RT-PCR assays using primers in exons 10 and 11,
exons 11 and 14, and exons 25 and 27. However, using primers in
exons 1 and 3, we were able to detect a small amount of BRCA2
product (10- to 50-fold less than in the other cell lines tested). As
the methylation status of the BRCA2 promoter in this cell line
appears to be no different from that of other cell lines or normal
tissues, this difference in expression must be due to other factors.
DISCUSSION
We found no evidence ofmethylation ofCpG dinucleotides within
the BRCA2 promoter region in any of the tissues examined. It is
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Figure 4 Competitive RT-PCR assay of BRCA2against actin in breast and ovarian cell lines. The cell line Hb4a - an SV40 large T antigen immortalized cell
line derived from normal breast epithelial cells - was used to normalize the levels of BRCA2being expressed in all the other breast and ovarian cancer cell lines
that were examined. This was done after 20 cycles of the PCR (A) and again after 25 cycles of the PCR (B). The graphs indicate that there are no significant
differences in the levels of BRCA2 expressed between cell lines homozygous at this locus and cell lines heterozygous at the locus. It also shows that the
number of cycles of PCR does not substantially influence the result. The experiment was carried out twice to confirm the result (downwards pointing arrows
indicate where the PCR has failed)
possible that examination ofjust three CpG dinucleotides does not
adequately reflect the methylation status ofthe more than 50 CpG
dinucleotides within the BRCA2 CpG island. However, in previous
studies of MTS1, RBI, E-cadherin and VHL (Ohtani Fujita et al,
1993; Herman et al, 1994, 1995; Yoshiura et al, 1995), increases in
methylation of the promoter regions in cancers were associated
with increases in methylation at all the CpG dinucleotides studied.
Moreover, it is unlikely that methylation ofonly one BRCA2 allele
was missed, as the results were identical in cell lines and primary
cancers that are heterozygous for chromosome 13q markers and
for those that have apparently lost heterozygosity.
Therefore, the absence of somatic mutations of BRCA2 in
sporadic breast and ovarian cancers remains puzzling; it is even
more so because BRCA] exhibits a remarkably similar pattern.
BRCAJ germline mutations predispose to breast and ovarian
cancer (Miki et al, 1994), the wild-type BRCAI allele is lost in
cancers arising in carriers ofBRCAI germline mutations (Cornelis
et al, 1995), allele loss on chromosome 17q is seen commonly in
sporadic breast and ovarian cancers (Cropp et al, 1993) and no
somatic mutations of BRCAJ have yet been reported in sporadic
breast cancers, with only a few in ovarian cancers (Futreal et al,
1994; Hosking et al, 1995; Merajver et al, 1995).
The hypotheses that have been proposed to explain these obser-
vations fall into two major categories. One set makes the assump-
tion that the losses of heterozygosity observed in sporadic breast
and ovarian cancers on chromosomes 17q and 13q are directed at
BRCAI and BRCA2 respectively. Thus, somatic mutations in
BRCAI and BRCA2 are still to be discovered or an epigenetic
mechanism substitutes for somatic mutation. The present study
indicates that methylation-based transcriptional repression is
unlikely to be responsible for inactivation of the retained allele.
The second group of hypotheses assumes that the allele losses on
chromosomes 17q and 13q are not directed at BRCAJ and BRCA2,
respectively, but at other genes in the region. While this is plau-
sible, it leaves unaddressed the issue of why BRCAJ and BRCA2
are mutated so infrequently in sporadic cancers, as almost all other
cancer-susceptibility genes suffer somatic mutations in sporadic
cancers, albeit to a varying extent. One possibility is that BRCAJ
and BRCA2 are not easily mutable, although there is no obvious
reason for this. Another is that somatic mutations in BRCAJ or
BRCA2 do not actually provide substantial growth advantage to the
cells in which they occur. Indeed, carriers ofgermline mutations in
BRCAI or BRCA2 usually develop-only one or two breast cancers
over a lifetime, despite the fact that all breast epithelial cells carry
British Joumal of Cancer (1997) 76(9), 1150-1156
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the mutation. Finally, it is possible that BRCA] and BRCA2 muta-
tions contribute to oncogenesis only in the correct cellular context,
that the factors which define this context are restricted to a short
period during development (for example puberty) and are not
usually present in breast or ovarian epithelial cells that have
acquired somatic mutations in BRCAI or BRCA2.
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